Jazz Pharmaceuticals
JAZZ
231.19
-0.20
-0.09%
Jazz Pharmaceuticals
US · JAZZ
#1123 by market cap
Listed 1970
231.19
-0.20
-0.09%
Live - 5344 symbols - heartbeat 124s ago
· 2026-10-08 04:15
Pre-market
229.85
-0.58%
After-hours
231.19
0.00%
Overnight
231.85
+0.29%
- Market cap
- 15.01B
- P/E (TTM)i
- 15.82
- P/Bi
- 3.13
- EPSi
- -5.84
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on JAZZ?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.7 percentage points.
Institutional ownership
- Held by institutions
- 100.63% -0.68pp
- Institutions
- 778 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund80.84%
Hedge Fund11.48%
Individual/Insider2.90%
Public Company2.67%
Government Pension Fund1.61%
Private Company1.47%
Sovereign Wealth Fund1.01%
VC/PE Fund0.87%
Insurance Company0.34%
Top holders as of 2026-06-30
BlackRock
9.19% · 5.97M sh
FMR
7.03% · 4.57M sh
Vanguard Capital Management, LLC
4.81% · 3.12M sh
Vanguard Portfolio Management, LLC
4.68% · 3.04M sh
Capital Research
4.16% · 2.70M sh
LSV Asset Management
3.50% · 2.28M sh
Franklin Resources
3.14% · 2.04M sh
State Street Global Advisors
3.08% · 2.00M sh
Dimensional Fund Advisors
2.64% · 1.71M sh
Fuller & Thaler Asset Management, Inc.
2.52% · 1.64M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 13 buys · 37 sells
| Name | Role | Stake |
|---|---|---|
| Seamus Mulligan | Independent Director | 1.98% |
| Bruce Cozadd | Chairperson & CEO | 0.48% |
| Renee Gala | President | 0.08% |
| Kenneth O’Keefe | Independent Director | 0.04% |
| Robert Iannone | Executive VP and Global Head of Research & Development | 0.04% |
| Philip Johnson | Chief Financial Officer | 0.04% |
| Samantha Pearce | Senior Vice President of Europe & International | 0.03% |
| Neena Patil | Chief Legal Officer | 0.03% |
| Patrick Gerald Enright | Independent Director | 0.03% |
| Heather McSharry | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Bruce Cozadd | Chairperson & CEO | Automatic Disposition | -6,000 | $230.33 |
| 2026-09-09 | Neena Patil | Chief Legal Officer | Automatic Disposition | -1,200 | $240.94 |
| 2026-09-07 | Renee Gala | President | Sale to Issuer | -1,967 | $246.81 |
| 2026-09-07 | Renee Gala | President | Automatic Disposition | -2,000 | $243.03 |
| 2026-09-07 | Mary Henderson | Senior Vice President of Technical Operations | Sale to Issuer | -1,427 | $241.20–243.03 |
| 2026-08-31 | Bruce Cozadd | Chairperson & CEO | Automatic Disposition | -6,000 | $250.13 |
| 2026-08-30 | Bruce Cozadd | Chairperson & CEO | Sale to Issuer | -1,219 | $241.39–244.06 |
| 2026-08-30 | Norbert Riedel | Independent Director | Sale to Issuer | -1,706 | $241.39–244.64 |
| 2026-08-30 | Ted Love | Director | Sale to Issuer | -743 | $241.39–244.06 |
| 2026-08-30 | Patrick Gerald Enright | Independent Director | Sale to Issuer | -1,706 | $241.39–244.64 |
| 2026-08-30 | Patrick Kennedy | Independent Director | Sale to Issuer | -1,855 | $241.39–244.06 |
| 2026-08-30 | Rick Winningham | Lead Independent Director | Sale to Issuer | -1,706 | $241.39–244.64 |
| 2026-08-30 | Jennifer Cook | Independent Non-Executive Director | Sale to Issuer | -1,706 | $241.39–244.06 |
| 2026-08-30 | Laura Hamill | Independent Director | Sale to Issuer | -1,706 | $241.39–244.06 |
| 2026-08-30 | Heather McSharry | Independent Director | Sale to Issuer | -1,855 | $241.39–244.64 |
| 2026-08-30 | Mark Smith | Independent Non-Executive Director | Sale to Issuer | -1,706 | $241.39–244.64 |
| 2026-08-30 | Mary Henderson | Senior Vice President of Technical Operations | Sale to Issuer | -2,092 | $241.39–244.64 |
| 2026-08-26 | Robert Iannone | Executive VP and Global Head of Research & Development | Automatic Disposition | -19,421 | $250.60–252.76 |
| 2026-08-26 | Robert Iannone | Executive VP and Global Head of Research & Development | Derivative Exercise and Sale | -57,500 | $113.10–250.60 |
| 2026-08-06 | Anne O'Riordan | Independent Director | Intent to Sell (Form 144) | -3,507 | $251.58 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:15:57 · For reference only, not investment advice and not tailored to your situation.